TScan Therapeutics (TCRX) Competitors $1.62 -0.12 (-6.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.58 -0.05 (-2.78%) As of 08/1/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX vs. PVLA, FULC, GOSS, TECX, ETON, AQST, ARCT, CMPS, SNDL, and CYRXShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Palvella Therapeutics (PVLA), Fulcrum Therapeutics (FULC), Gossamer Bio (GOSS), Tectonic Therapeutic (TECX), Eton Pharmaceuticals (ETON), Aquestive Therapeutics (AQST), Arcturus Therapeutics (ARCT), COMPASS Pathways (CMPS), SNDL (SNDL), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Its Competitors Palvella Therapeutics Fulcrum Therapeutics Gossamer Bio Tectonic Therapeutic Eton Pharmaceuticals Aquestive Therapeutics Arcturus Therapeutics COMPASS Pathways SNDL CryoPort TScan Therapeutics (NASDAQ:TCRX) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership. Is TCRX or PVLA more profitable? Palvella Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -2,974.08%. TScan Therapeutics' return on equity of -55.76% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-2,974.08% -55.76% -36.56% Palvella Therapeutics N/A -60.29%-43.30% Which has more volatility and risk, TCRX or PVLA? TScan Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Does the media refer more to TCRX or PVLA? In the previous week, Palvella Therapeutics had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Palvella Therapeutics and 1 mentions for TScan Therapeutics. Palvella Therapeutics' average media sentiment score of 1.53 beat TScan Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend TCRX or PVLA? TScan Therapeutics presently has a consensus price target of $7.80, indicating a potential upside of 381.48%. Palvella Therapeutics has a consensus price target of $47.50, indicating a potential upside of 29.96%. Given TScan Therapeutics' higher probable upside, equities research analysts clearly believe TScan Therapeutics is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has stronger valuation & earnings, TCRX or PVLA? Palvella Therapeutics has higher revenue and earnings than TScan Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$2.82M32.51-$127.50M-$1.09-1.49Palvella Therapeutics$42.81M9.44-$17.43M-$12.10-3.02 Do insiders and institutionals have more ownership in TCRX or PVLA? 82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 4.4% of TScan Therapeutics shares are held by company insiders. Comparatively, 20.5% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryPalvella Therapeutics beats TScan Therapeutics on 9 of the 17 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.47M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.4917.6228.7523.81Price / Sales32.51179.21372.2066.02Price / CashN/A41.9535.4557.96Price / Book0.388.508.275.55Net Income-$127.50M-$55.06M$3.25B$259.20M7 Day Performance-16.06%-3.99%-3.72%-4.64%1 Month Performance10.20%9.58%4.30%4.41%1 Year Performance-75.86%6.70%25.87%17.95% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics3.1632 of 5 stars$1.62-6.9%$7.80+381.5%-76.3%$98.47M$2.82M-1.49100Gap DownPVLAPalvella Therapeutics2.6822 of 5 stars$39.87+3.2%$47.50+19.1%N/A$426.97M$42.81M-3.30N/AFULCFulcrum Therapeutics2.2606 of 5 stars$7.81flat$6.29-19.5%-24.2%$421.58M$80M-111.56100Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGOSSGossamer Bio3.9096 of 5 stars$1.98+7.6%$8.25+316.7%+127.3%$418.24M$114.70M-8.61180News CoveragePositive NewsOptions VolumeTECXTectonic Therapeutic2.8961 of 5 stars$22.74+1.9%$80.33+253.3%+16.7%$416.77MN/A-3.11120News CoverageETONEton Pharmaceuticals1.8975 of 5 stars$15.03-2.4%$29.67+97.4%+289.3%$412.99M$39.01M-83.5020News CoverageUpcoming EarningsAQSTAquestive Therapeutics1.7153 of 5 stars$4.00-3.6%$10.14+153.6%+6.4%$412.21M$57.56M-6.78160Upcoming EarningsARCTArcturus Therapeutics3.0347 of 5 stars$14.38-3.7%$54.00+275.5%-43.0%$405.18M$152.31M-5.68180Positive NewsCMPSCOMPASS Pathways2.7759 of 5 stars$4.34+0.2%$17.00+291.7%-36.9%$405.12MN/A-2.18120News CoveragePositive NewsEarnings ReportAnalyst ForecastSNDLSNDL2.6343 of 5 stars$1.50-1.0%$4.00+166.7%-25.3%$398.11M$671.81M-5.172,516Trending NewsEarnings ReportAnalyst RevisionCYRXCryoPort2.1548 of 5 stars$7.65-2.5%$11.11+45.2%-16.4%$393.58M$228.38M-3.271,186Upcoming EarningsGap Down Related Companies and Tools Related Companies Palvella Therapeutics Competitors Fulcrum Therapeutics Competitors Gossamer Bio Competitors Tectonic Therapeutic Competitors Eton Pharmaceuticals Competitors Aquestive Therapeutics Competitors Arcturus Therapeutics Competitors COMPASS Pathways Competitors SNDL Competitors CryoPort Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts